Hm concentration necessary of mutant single step. MIC test uses an infectious dose of about 105 to 106 CFU / ml, which has some disadvantages. TW-37 MIC test not emulate the bacterial load associated with many infections and can not recognize, resistant mutant subpopulations that may be present k. Since MPC test, an h Here infective dose, this technique can be useful to determine the effectiveness of antibiotics in preventing selection of resistant mutants. Inocula in this study were lower than those reported by other researchers. However, the mutation frequency for fluoroquinolones 1106-1 in 109 cells, we reached the inoculum means was sufficient to detect mutant subpopulations. A conversation Ch about the difficulty of arriving at an inoculum of 1011 CFU / ml can be found elsewhere.
Although the MPC concept does not apply to all antibiotics and all bacteria can present the concept of a return to the activity T fluoroquinolones against various pathogens. One of the major mechanisms of fluoroquinolone resistance include chromosomal NPI-2358 Ver Changes induced in the target sites, topoisomerase II and topoisomerase IV Previous studies suggest that these mutations allm Hlich occur. The MPC concept applies to fluoroquinolones because the theory is that the achievement of the MPC is the continued growth of mutants, the first step to prevent. Thus, maintaining a concentration above the MPC, au OUTSIDE of the MSW, is desirable. The maximum concentrations with a free clinical dose of levofloxacin, moxifloxacin and gatifloxacin are obtained are at or above the MPCs for all isolates in this study.
Clinical dosing for ABT 492 is still open. Firsov et al. suggest that the enrichment of resistant subpopulations of Staphylococcus aureus occur if fluoroquinolone concentrations remain within the MSW for 20% of the dosing interval. W During ABT 492 offers no advantage in terms of size E of the MSW, because the MPC is much lower than that of levofloxacin, moxifloxacin or gatifloxacin, clinical dose of ABT 492 may be able to provide a concentration gr it to achieve than the MPC, au OUTSIDE of MSW, a gr larger part of the dosing interval. In summary, we show that, although the size E of the MSW is important that the prime Ren clinical should be taken into account whether drug concentrations at the site of infection h Higher than the MPC.
Therefore, the h HIGHEST rate / MPC, the time of concentration above the MPC remains outside of the MSW, the MSW can be used as clinically relevant. This work was supported by Abbott Laboratories. ABT 492 is an experimental fluoroquinolone with activity t against Gram-negative and gram-positive bacteria that cause infections of the respiratory tract, including normal causing Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarralis. This medication is known that up to 64 times more active than other fluoroquinolones gegenw Ships for use against S. pneumoniae. This study was conducted to determine the in vitro activity of t ABT 492 against many clinical isolates of Ureaplasma and Mycoplasma species known to cause human disease rate. ABT 492 was studied in comparison with other fluoroquinolones, macrolides, lincosamides, and doxycycline. Bactericidal activity were Th against these organisms by determining CMB and measure the dynamics of the abbot Tion of bacteria with time t Based tests for selected COOLED studied isolates. Mycoplasma pneumoniae